Home » Thought Leadership » Page 9

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 108 posts
Tumour case study
March 24, 2020 | Blog

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.

Elena Subbotina smiling in front of a city backdrop
March 24, 2020 | Culture Blog

Entrepreneurialism at CBPartners: The Wiki Initiative

The development of CBPartners’ work and culture is shaped by consultants at all levels. Entrepreneurialism thrives at the firm, with naturally curious individuals driving both internal and external initiatives.

Gene editing case study
March 24, 2020 | Blog

Genome Editing: An Introduction

A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.

March 20, 2020 | Culture Videos

Diversity Makes Us Great, Together.

CBPartners supports each individual uniquely in growing their career with us. We search for people with different backgrounds, skills, and perspectives during our hiring process because maintaining a diverse workforce is what enables us to present our clients with the most developed and strategic insights that are truly spoken through a global lens.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
March 17, 2020 | Podcasts

CBPartners’ Pharma Take-Away: COVID-19 (Pt 1): Roundtable

In this episode, Jared Wolff is joined by Matthew Rube and Akhil Parlapalli from CBPartners' New York office to discuss some of the topics surrounding the novel coronavirus (COVID-19) pandemic: